Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

An antibody agreement
June 2016
SHARING OPTIONS:

BELFAST, U.K. & NEURIED, Germany—Fusion Antibodies and MAB Discovery recently announced their intent to begin a research and license agreement in monoclonal antibodies. Under the collaboration, Fusion Antibodies will leverage its proprietary CDRx Multiplex platform to humanize therapeutic antibodies selected and produced by MAB Discovery, which will provide potential partners with high-quality humanized antibodies ready for further development.
 
“We are very pleased to be working with Fusion Antibodies, a well-respected antibody engineering firm with strong expertise in humanization,” Dr. Stephan Fischer, CEO of MAB Discovery, said in a press release. “The planned collaboration will enable us to provide our customers added value by offering high-quality humanized antibodies that are ready to be validated and brought into development. We also expect that combining our technologies will reduce the time from target to clinical candidate.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.